Carboplatin

For research use only.

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

33 publications

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 57 In stock
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Carboplatin has been cited by 33 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.
Features A DNA synthesis inhibitor.
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  M3ruWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fwflIuOjYkgJpOwG0> MVy3NkBp M2rKZolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M{DJUlI3OTN5MUC1
Tca8113/CBP  Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOyMVI26oDLzszN NHX4PXo4OiCq MXnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NHy3SZUzPjF|N{GwOS=>
Tca8113/PYM  NV\HSGc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[yMVI26oDLzszN NXfDNolFPzJiaB?= MWDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MkSzNlYyOzdzMEW=
SKOV3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHRZXluPjBibXevcYw> MoLTNU02KGR? MWnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSC2aX3lJIRmeGWwZHXueIx6 M1Gy[VI3OTN5MESz
SKOV3 NITCepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3kNE01KM7:Zz;tcC=> M3vLfVI1NzR6L{eyJIg> NUiyTpoycW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NGrOSlkzPjF{NUK3Ny=>
SKOV3 NVThPWRISXCxcITvd4l{KEG|c3H5 MlL6NkDPxGdxbXy= MUC0PEBp NYTzRZI6cW6mdXPld{BieG:ydH;zbZM> NX70c|ZtOjZzMkWyO|M>
OSA M2[wW2Ntd26xZ3XubYMhSXO|YYm= NHfDOFAzNjVxNTFOwG0> NUjrSoVEemW|dXz0d{BqdiCub4fldkBkd2yxbomg[o9zdWG2aX;uJIF{KGOxbYDhdoVlKHSxIHXpeIhmeiCETVmxJJNqWk6DIITy[YF1dWWwdB?= M1TQZVI3OTFyNkKw
A549 NVftU25xTnWldHnvckBCe3OjeR?= M4DwZlAwOjVxNUCg{txO MV[yOEBp M3joO4Rwf26{ZXf1cIF1\XNibXnSMVIxPSCneIDy[ZN{cW:wwrC= NXT6O|JOOjV7MUezNVc>
H1975 M4PhTmZ2[3Srb36gRZN{[Xl? NVH2RXpXOC9{NT:1NEDPxE1? NFXpfpAzPCCq NUPpPIw4\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=> NYP0OHM4OjV7MUezNVc>
A549 MmHySpVkfGmxbjDBd5NigQ>? MoHBNE8zPS93MDFOwG0> NFrpfmozPCCq MVr1dJJm\3WuYYTld{BucVJvMkG4JIV5eHKnc4Ppc44> MojaNlU6OTd|MUe=
H1975 M3X6e2Z2[3Srb36gRZN{[Xl? MmTzNE8zPS93MDFOwG0> MW[yOEBp NU\tUHFbfXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w Mo\UNlU6OTd|MUe=
A549 NX\pXmVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MViyOUDPxE1? NXf2XY5XOjRiaB?= M2XWSIlvcGmkaYTzJINmdGxiZ4Lve5Rp MnPBNlU6OTd|MUe=
H1975 NHfGepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHYNlUh|ryP MmXmNlQhcA>? MlG4bY5pcWKrdIOgZ4VtdCCpcn;3eIg> NYf1dWx4OjV7MUezNVc>
MDA-MB-231 MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T2clAuOjJyIN88[{9udA>? NWSwVFB5PzJiaB?= NELYPYlKSzVywrC9JFg3KM7:TR?= M3zRNVI2QDN5Nkmx
T47D MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknINE0zOjBizsznM41t Mlv4O|IhcA>? NFXQdmZKSzVywrC9JFQ5NjlizszN M3vMfFI2QDN5Nkmx
LCTCC NUf3ZXgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4iwW2lEPTB;Mz645qCKyrWP MljaNlU4PzNzNke=
MCTCC NHvaS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzhS2pZUUN3ME2yMljjiIoEtV2= M1frcVI2Pzd|MU[3
MegTCC M{fne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonrTWM2OD12LkJihKnDvU1? MUSyOVc4OzF4Nx?=
MonoTCC NFTNXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPLVXZKSzVyPUWuOwKBkcL3TR?= M4[4flI2Pzd|MU[3
MCF7 MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\pTZNCOjBizszN M33sSVczKGh? MXLpcoR2[2W|IHPlcIwh\GWjdHigc4YhUFBzzsKt[IVxdGW2ZXSgUWNHPyClZXzsdy=> MkfINlU4PjlyMkW=
A-549  NGqxUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED3UmoxNjVizszN M2jiflI1KGh? NYCyb2lFTE2VT9Mg MlTFbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= NUK4WmQ2OjV5NUW2PVA>
A-549  MnLxRZBweHSxc3nzJGF{e2G7 M13sfVAvPSEQvF2= MkjnOFghcA>? MW\EUXNQyqB? Ml3yd4hwf3NiZXHycJkh[XCxcITvd4l{KG[nYYT1doV{KGmwY3z1[Ilv\yCkbHXiZolv\yCjbnSgZ4hzd22jdHnuJINwdmSnboPheIlwdg>? MmnMNlU4PTV4OUC=
A-549  MXnGeYN1cW:wIFHzd4F6 MYWwMlUh|ryP NV\ydHM4PDhiaB?= M162cWROW00EoB?= M4rh[ZNpd3e|IHHi[ZJz[W62IH3pZ5JwfHWkdXzlJIRqe3K3cITpc44> NWD4bWkxOjV5NUW2PVA>
A-549  MmrYSpVkfGmxbjDBd5NigQ>? MV6wMlUh|ryP MX:0PEBp MY\EUXNQyqB? MmfxbY5pcWKrdIOgc4Yh[2WubDDtbYdz[XSrb39CpC=> M{fnelI2PzV3Nkmw
RMG-1 NIHKTWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTrTWNmUUN3ME2yPE45KMLzIEOuOkBu\y:O MlW5NlU4OjZ7MUO=
FN-RMG-1 NXPYXXExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPUTWM2OD12MD61JOKyKDRwMjDt[{9NEiEQvF2= M1XtelI2PzJ4OUGz
RMG-1-hFUT MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrTfVFKSzVyPUW4MlEhyrFiMj60JI1oN0x? MXqyOVczPjlzMx?=
FN-RMG-1-hFUT NV\lZW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrLR2VKSzVyPUGxPE45KMLzIEGzMlghdWdxTB?= NVH5NohQOjV5Mk[5NVM>
CHP-134  NIL0VYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnZNUDPxE1? MYXEUXNQyqB? M1\t[olvcGmkaYTzJJNq\26rZnnjZY51KGOnbHyg[5Jwf3SqIHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? MVmyOVY2QDR4Mx?=
IMR-32 M{f0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfwcpJ4OSEQvF2= NIexNohFVVORwrC= MkjIbY5pcWKrdIOgd4lodmmoaXPhcpQh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBIW0t{OEOwN|cy MVGyOVY2QDR4Mx?=
CHP-134  MnLTSpVkfGmxbjDBd5NigQ>? MoexNVAh|ryPwrC= MV;EUXNQyqB? MnLvbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> M4fzOFI2PjV6NE[z
IMR-32 NILLOGhHfWO2aX;uJGF{e2G7 MmnVNVAh|ryPwrC= NETZdJVFVVORwrC= MorlbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> MWCyOVY2QDR4Mx?=
A549 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTDcpFOOC5{LUSwNFAh|ryP NF7NVGk4OiCq M3zlW2lEPTB;MUK2JOKyKDVwMDFOwG0> MWKyOVYzPTJ2Mx?=
A549/CDDP NHjRPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;WNE4zNTRyMECg{txO MkfoO|IhcA>? MnizTWM2OD1{NEFCpOKyyqB2NT63JO69VQ>? NUnMVmdwOjV4MkWyOFM>
H460  MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHuyOHUzPCCq NE\RU2lFVVOR M3PFXmlEPTB;Nz65JO69VQ>? M{\zWVI2PTl7OUm1
H460  MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zPWVcvQSEQvF2= M2\CbVI1KGh? MWfEUXNQ MX7zbI94eyCjIILh[Ilwe2Wwc3n0bZpqdmdiZX\m[YN1KHSxIGitdoF6ew>? NXvkXnk5OjV3OUm5PVU>
NRK-52E M1\SNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Xme|czyqCqwrC= MW\JR|UxRTFyMDFCtUAyOi57IN88US=> NFXkOoEzPTV4NU[wNy=>
RGE MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYm3NuKhcMLi MoPTTWM2OD1{MjFCtUA4NjRizszN NIDrS2kzPTV4NU[wNy=>
NRK-52E NH\1RZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:3NuKhcMLi M3HjTGlEQDB;MUe5JOKyKDlwNTFOwG0> M3OzZlI2PTZ3NkCz
RGE MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfJO|LDqGkEoB?= NGH0WHdKSzhyPU[zJOKyKDdwNDFOwG0> M4[1SFI2PTZ3NkCz
SK-OV-3 MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf6doJiPzJiaB?= NH2xcXVKSzVyPUGwOE45KM7:TR?= NYq0W2h[OjV3MkCxN|I>
ES-2 NVTwXGk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYi3NkBp MXnJR|UxRTF2Lk[g{txO NIqyTJMzPTV{MEGzNi=>
OVCAR-8 M4fkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\FNpo4OiCq MVLJR|UxRTl4LkCg{txO MXiyOVUzODF|Mh?=
3AO NGnJUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKxbpc4OiCq M1vNOmlEPTB;NkOuOEDPxE1? NWLFSoZYOjV3MkCxN|I>
A2780 NVnHXW85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonuO|IhcA>? MnexTWM2OD1zNEWuO{DPxE1? MoDiNlU2OjBzM{K=
SW626 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVG3NkBp NFfySFJKSzVyPUm3MlAh|ryP NWD2TVFqOjV3MkCxN|I>
OVCAR-3 NYHSSotOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYq2VXVUPzJiaB?= MVvJR|UxRTN{Lk[g{txO NH;GbI0zPTV{MEGzNi=>
A549 M3PYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF3MT61OkDDuSB3Mz6wOkDPxE1? NIXrWHUzPTJ5N{S2NS=>
4T1 Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTh2Lk[yJOKyKDNyLkC1JO69VQpizszN MmnHNlUzPzd2NkG=
BALB/3T3 Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF2LkOwJOKyKDZwNkig{txO MnzzNlUzPzd2NkG=
B16 Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\JV5RWUUN3ME22OE4{OCEEsTC2MlgyKM7:TR?= NYHiZ2xqOjV{N{e0OlE>
DU 145 NUTKc|dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e4RWlEPTB;M{WuNFQhyrFiMUeuOVQh|ryP MkT0NlUzPzd2NkG=
FaDu Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLR[HFSUUN3ME20OU4{QSEEsTCxNU42OCEQvF2= NE\wPI4zPTJ5N{S2NS=>
HCV-29T MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTR6LkW3JOKyKDJ{LkS5JO69VQ>? MnPONlUzPzd2NkG=
HL-60 NEK2WGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfiTWM2OD1zMT6xNEDDuSB2LkS3JO69VQ>? NXTyWGg3OjV{N{e0OlE>
HT-29 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnJToptUUN3ME24PU4yPiEEsTCxPE45PiEQvF2= NXjQe4FVOjV{N{e0OlE>
H146 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;DcYtKSzVyPUS5MlbDuTF|LkGg{txO MWmyOVEzPDJ6Mh?=
H187 NV33VWNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu4TWM2OD1zMj63xtEzNjdizszN Ml\DNlUyOjR{OEK=
H128 Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f3PWlEPTB;MUC2MlTDuTlwNjFOwG0> M3;3O|I2OTJ2Mkiy
H69 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTd4LkpCtVI4NjhizszN Mo\WNlUyOjR{OEK=
H209 NY\NUFZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M331SGlEPTB;MkW4MlHDuTl7Lkig{txO MYKyOVEzPDJ6Mh?=
DMS153 M{[yTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTV5LklCtVkvOiEQvF2= M17MVVI2OTJ2Mkiy
H526 NWHudng2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\MNGlEPTB;Nz6yxtEyNjdizszN MlrXNlUyOjR{OEK=
DMS114 NE\JXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoG5TWM2OD16NT64xtEyOi56IN88US=> NVS3ZnIxOjVzMkSyPFI>
DMS53 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF2Nj6yxtE{Pi52IN88US=> M{nIdVI2OTJ2Mkiy
HeLa NV\y[HNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\DTGRqPS16MDFOwG0> Mn70bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MXmyOVExQTN4MB?=
MCF-7 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P3e|UuQDBizszN Ml\LbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M1nHS|I2OTB7M{[w
MDA-MB-231 M1H5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDFN5lMPS16MDFOwG0> MlXKbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M2PzRlI2OTB7M{[w
CaOV3 NWL6[Ws3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:3NkBp Moi1TWM2OD16Nj6xJO69VQ>? MV6yOVA3QDh2OR?=
OVCAR-3 Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\ZVFczKGh? M4DIVGlEPTB;MUe5MlUh|ryP NFy0blUzPTB4OEi0PS=>
OVCAR-5 NXLHZ3FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPsXVRRPzJiaB?= NHrpRVRKSzVyPUe1Mlch|ryP M1XnWlI2ODZ6OES5
SKOV-3 M1TJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u5UlczKGh? NUfuOpBvUUN3ME21NFQh|ryP MlLBNlUxPjh6NEm=
OVCAR-4 NHnKN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWO3NkBp NFPHTpRKSzVyPUK5NE43KM7:TR?= MUOyOVA3QDh2OR?=
OVCAR-8 NHTufWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV23NkBp NV:wVXl7UUN3ME22PVAvOiEQvF2= NFTzRngzPTB4OEi0PS=>
MA148 M2HPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj0NlQhcA>? M3jvdWlEPTB;OEOuOwKBkcLz4pEJNU41KM7:Zz;tcC=> MkXYNlQ5OzFyOUG=
A549 NHv6N4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXINlQhcA>? MXPJR|UxRTd5Nj6w5qCKyrIkgJmxMlkh|rypL33s NIPodGUzPDh|MUC5NS=>
MDA-MB-231 NGnTXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17tTFI1KGh? NUG0dIxHUUN3ME23OFgvOOLCidMx5qCKOS5zIN88[{9udA>? MlTsNlQ5OzFyOUG=
NCI-ADR/RES  NIGyVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXXUGNwOjRiaB?= NFrBT4pKSzVyPUG3OVMvOOLCidMx5qCKPC52IN88[{9udA>? MWCyOFg{OTB7MR?=
MA148 NVzucIkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonXOFghcA>? NVLxOHQ5UUN3ME2yPE4y6oDLwsJihKkyNjBizsznM41t NH3kOFEzPDh|MUC5NS=>
A549 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXtdGQ1QCCq NGfHUZpKSzVyPUGxPE4x6oDLwsJihKkyNjJizsznM41t MUOyOFg{OTB7MR?=
MDA-MB-231 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXy0PEBp NFywUXpKSzVyPUG4N{4x6oDLwsJihKkyNjJiIN88[{9udA>? M4K5XlI1QDNzMEmx
NCI-ADR/RES  MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF23[2U1QCCq NITG[WlKSzVyPUG5N{4x6oDLwsJihKkyNjlizsznM41t NG\uZYQzPDh|MUC5NS=>
MA148 NWjTSWxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HUVVczKGh? M1TZbWlEPTB;MUOuO-KBkcLz4pEJNU4zKM7:Zz;tcC=> NYH3RmQzOjR6M{GwPVE>
A549 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULXbIUzPzJiaB?= NU\WeJhuUUN3ME22OE4{6oDLwsJihKkyNjFizsznM41t MnLPNlQ5OzFyOUG=
MDA-MB-231 M3f6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf4SZQ4OiCq NFPxSVVKSzVyPUm5MlXjiIoEsfMAjVEvOSEQvHevcYw> NFTsVoszPDh|MUC5NS=>
NCI-ADR/RES  NIewdlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVO3NkBp MVTJR|UxRTN5LkVihKnDueLCiUGuO{DPxGdxbXy= NVfBco5zOjR6M{GwPVE>
A549 NI\DS2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO5[HlbPzJiaB?= NH\LNWNFVVOR MmGyTWM2OD1zNUKuOFA6KM7:TR?= NHu0N3MzPDd{MUOyNy=>
NCI-H157 M37Sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M134RlczKGh? M1T2S2ROW09? Mln6TWM2OD16OT65O|ch|ryP NETHS5UzPDd{MUOyNy=>
PC9 MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\rZlczKGh? M1G5UGdEPTB;N{GuOuKyQS53INM1US=> NWD6VGpSOjR4MUi4NFk>
A549  NInCXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX2O404OiCq MUHHR|UxRTF|NtMxN|EvPiEEtV5CpC=> M3Tw[FI1PjF6OEC5
PC9 M3;VT2Fxd3C2b4Ppd{BCe3OjeR?= NIPndpkyODBiwsXN MWm3NkBp MYDpcoR2[2W|IHHwc5B1d3Orcx?= MWSyOFYyQDhyOR?=
A549  MoTxRZBweHSxc3nzJGF{e2G7 NYm2R5hROTByINM1US=> MYe3NkBp NFnV[FVqdmS3Y3XzJIFxd3C2b4Ppdy=> M{XPe|I1PjF6OEC5
A549 M{fQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTVOoNsOjRiaB?= M3O0OGlEOTB;MT60O|Yhdk1? NF\2fmEzPDN7NkSzOy=>
H1299 Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[yOEBp NWTINVhPUUNzME2wMlQ1OyCwTR?= NFS4bYgzPDN7NkSzOy=>
HCC15 NX7We4I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rLdVI1KGh? MYHJR|ExRTBwM{S2JI5O MUOyOFM6PjR|Nx?=
H157 NIqxeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLkXHMzPCCq NHH5Z3BKSzFyPUCuPFEhdk1? NWLG[G5UOjR|OU[0N|c>
A2780 NYftWplKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn4VXNJUUN3ME2xOE4x6oDLwsJihKkyNjRizszN NYOwWHdqOjR{MEm2PVM>
A2780cisR MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoWxTWM2OD12OD655qCKyrIkgJmzMlkh|ryP M3HKeFI1OjB7Nkmz
A2780ZD0473R MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H3WGlEPTB;NkSuOwKBkcLz4pEJN{4zKM7:TR?= M3nXPFI1OjB7Nkmz
SKOV-3 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTR|LkVihKnDueLCiUOuPUDPxE1? NXvsbVc{OjR{MEm2PVM>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pChK-2 / Chk-2 ; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p38 / p38 / Cleaved PARP / PARP ; 

PubMed: 30049957     


A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋€𢡄�෋€䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemセ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒セ᎒�堞ﻮ᎒፲露𢡄

30049957
Immunofluorescence
γH2AX ; 

PubMed: 24348048     


Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ

24348048
Growth inhibition assay
Cell viability ; 

PubMed: 24348048     


SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay. 

24348048
In vivo In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Dosages: ≤60 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage powder
temperature in solvent (should be freshly prepared each time)
Synonyms JM-8, CBDCA, NSC 241240
Smiles N.N.[Pt++].[O-]C(=O)C1(CCC1)C([O-])=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04354961 Not yet recruiting Drug: Almonertinib|Drug: Paclitaxel and carboplatin Pulmonary Adenosquamous Carcinoma Fujian Cancer Hospital|Jiangsu Hansoh Pharmaceutical Co. Ltd. June 2020 Phase 2
NCT04222426 Recruiting Other: 89Zr-atezolizumab PET scans Lobular Metastatic Breast Cancer University Medical Center Groningen December 18 2019 Not Applicable
NCT04163094 Recruiting Drug: W_ova1 Vaccine Ovarian Cancer University Medical Center Groningen|Biontech RNA Pharmaceuticals GmbH November 25 2019 Phase 1
NCT04125446 Recruiting -- Cancer|Pregnancy University Hospital Gasthuisberg October 15 2019 --
NCT03968653 Recruiting Drug: Debio 0123|Drug: Carboplatin Advanced Solid Tumors Debiopharm International SA July 30 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID